TY - JOUR T1 - Clinical and Non-clinical Proof of Concept Supporting the Development of RJX As an Adjunct to Standard of Care Against Severe COVID-19 JF - medRxiv DO - 10.1101/2022.02.12.22270748 SP - 2022.02.12.22270748 AU - Fatih M. Uckun AU - Muhammad Saeed AU - Mustafa Awili AU - Ibrahim H. Ozercan AU - Sanjive Qazi AU - Cynthia Lee AU - Adeel Shibli AU - Alan W. Skolnick AU - Alonso Prusmack AU - Joseph Varon AU - Cesar I.P. Barrera AU - Cemal Orhan AU - Michael Volk AU - Kazim Sahin Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/02/18/2022.02.12.22270748.abstract N2 - Background The identification of effective strategies capable of reducing the case mortality rate of high-risk COVID-19 is an urgent and unmet medical need. We recently reported the clinical safety profile of RJX, a well-defined intravenous GMP-grade pharmaceutical formulation of anti-oxidant and anti-inflammatory vitamins as active ingredients, in a Phase 1 study in healthy volunteers (ClinicalTrials.gov Identifier: NCT03680105) (Uckun et al., Front. Pharmacol. 11, 594321. 10.3389/fphar.2020.594321). Here we report data from a pilot clinical study (RPI-015) which examined the safety, tolerability, and feasibility of using RJX in combination with clinical standard of care (SOC) in hospitalized COVID-19 patients with pneumonia (ClinicalTrials.gov Identifier: NCT04708340). In addition to our early clinical proof of concept (POC) data, we also present non-clinical POC from a mouse model of CRS and ARDS that informed the design of the reported clinical study.Methods 13 patients, who were hospitalized with COVID-19 pneumonia and abnormally elevated serum inflammatory biomarkers markers ≥3 months prior to the identification of the first confirmed U.S case of the Omicron variant, were treated with IV RJX (daily x 7 days) plus SOC. Non-clinical POC study examined the ability of RJX plus dexamethasone (DEX) to improve the survival outcome in the lipopolysaccharide (LPS)-Galactosamine (GalN) mouse model of fatal cytokine release syndrome (CRS), sepsis and acute respiratory distress syndrome (ARDS).Findings In the Phase 1 clinical study, none of the 13 patients developed a treatment-related DLT, SAE, or Grade 3-5 AEs. Nine (9) of the 12 evaluable patients, including 3 patients with hypoxemic respiratory failure, showed rapid clinical recovery. In the non-clinical POC study in LPS-GalN challenged mice, the combination of RJX plus DEX was more effective than RJX alone or DEX alone, reversed the CRS as well as inflammatory tissue damage in the lungs and liver, and improved the survival outcome. Taken together, these findings provide the early clinical and non-clinical POC for the development of RJX as an adjunct to the SOC in the multi-modality management of high-risk COVID-19.Competing Interest StatementAuthor FMU is employed by Ares Pharmaceuticals, and he serves as a consultant for Reven Pharmaceuticals. Author MV is a consultant and director at Reven Pharmaceuticals. Author CL is employed by Oncotelic Therapeutics, and she serves as a consultant to Reven Pharmaceuticals. All authors declare no other competing interests.Clinical TrialClinicalTrials.gov Identifier: NCT04708340Clinical Protocols https://clinicaltrials.gov/show/NCT04708340 Funding StatementThis study was funded by Reven Pharmaceuticals, LLC, a wholly-owned subsidiary of Reven Holdings Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The clinical study protocol was approved by the WCG-Central Institutional Review Board (IRB) (OHRP/FDA Parent Organization number: IORG0000432; OHRP/FDA IRB registration number: IRB00000533). The Central IRB-approved study/protocol number was RPI015 (IRB Tracking Number: 20203418). The study was performed in compliance with the International Conference on Harmonization (ICH) guidelines for Good Clinical Practice (ICHE6/GCP). Each patient provided a written informed consent (ICF) prior to enrollment. The non-clinical research project was approved by the Animal Care and Use Committee of Firat University (Project No. 03092020-391-047; Ethics Committee Number: 420629). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author. ER -